AZD 4547

Drug Profile

AZD 4547

Alternative Names: AZD4547

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dust Diseases Authority; Institute of Respiratory Health; National Cancer Institute (USA); University of Glasgow; University of Leeds; University of Wisconsin-Madison
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Phase II Breast cancer; Gastric cancer; Lung cancer; Mesothelioma; Oesophageal cancer
  • Phase I/II Glioblastoma; Solid tumours
  • Phase I Bladder cancer; Urogenital cancer
  • Preclinical Head and neck cancer

Most Recent Events

  • 13 Aug 2017 AstraZeneca and Hopitaux De Paris terminates a phase I/II trial in Glioblastoma (Late-stage disease, Second-line therapy or greater) in France, due to intermedary analysis of 12 first patients data results (NCT02824133)
  • 01 Jul 2017 University of Leeds completes a phase trial in Urogenital cancer, including Bladder cancer (Late-stage disease, Metastatic disease, Combination therapy) in United Kingdom (PO) (EuddraCT2011-004072-10)
  • 15 Jun 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top